News We’re Watching: Apple/Masimo Patent Fight Update; Acutus Winds Down; Illumina Bails On Grail

Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. In addition to the big news from Acutus, Apple, and Illumina, Masimo scored an important FDA clearance, Beta Bionics announced the US launch of its iLet bionic pancreas for Dexcom’s G7 CGM, and more.

Industry News We're Watching
• Source: Shutterstock

Under legal pressure from Masimo, Apple will stop selling the Apple Watch Ultra 2 and Apple Watch Series 9 in the US.

According to a report

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

What’s A Diagnostic? WHO Wants To Know

 
• By 

The World Health Organization is seeking input from stakeholders to create an official definition of the term ‘diagnostics.’ This initiative follows a 2023 resolution aimed at enhancing global diagnostics capacity; the definition, it is hoped, will help drive the creation of effective health policies. Comments will be accepted until 23 May.

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.